The Ultimate Guide to BHRT in Canada: Benefits, Risks, and Access

Bioidentical Hormone Replacement Therapy, or BHRT, is one of the most searched-for, misunderstood, and inconsistently described treatments in Canadian women’s health. Some clinics describe BHRT as a custom-compounded therapy. Others describe it as a Health Canada-approved prescription protocol. Both descriptions are accurate, and the difference matters.

This guide explains what BHRT actually is in Canada in 2026, who can prescribe it, what it costs, what the current evidence says about benefits and risks (including the major 2025-2026 regulatory shift on hormone therapy warnings), and how to access care through Red Leaf Wellness or another qualified provider.

What is BHRT in Canada?

Bioidentical Hormone Replacement Therapy uses hormones that are chemically identical, on a molecular level, to the hormones your own body produces. The most common hormones used in BHRT are estradiol, progesterone, and testosterone. They are typically derived from plant sources such as yams or soy, then synthesized in a laboratory to match the structure of human hormones exactly.

This is the part that gets confused most often: “bioidentical” describes the molecule, not the manufacturer. A Health Canada-approved estradiol patch from a major pharmaceutical company is bioidentical. A compounded estradiol cream from a specialty pharmacy is also bioidentical. The hormone is the same. What differs is how the product is manufactured, regulated, and dosed.

BHRT is most commonly prescribed for symptoms of perimenopause and menopause: hot flashes, night sweats, sleep disruption, mood changes, vaginal dryness, and changes in libido. It is also prescribed for low testosterone in men, for certain hormonal imbalances in younger women, and for bone protection in postmenopausal women.

Health Canada-approved bioidentical hormones vs compounded BHRT

This is the single most important distinction for anyone considering BHRT in Canada. Both options exist. Both can be appropriate. They are not the same.

Health Canada-approved bioidentical hormones

A range of bioidentical hormone products are approved by Health Canada and stocked at any standard Canadian pharmacy. These include:

• ✓Estradiol transdermal patches (such as Estradot and Climara)
• ✓Estradiol gels and sprays (such as Estrogel and Divigel)
• ✓Oral micronized progesterone (such as Prometrium)
• ✓Vaginal estradiol products for genitourinary symptoms
• ✓Testosterone gels and injections (primarily for men, with off-label use in women)

These products are manufactured to commercial pharmaceutical standards, undergo Health Canada review for safety and efficacy, and carry standardized dosing. In standard primary care, an approved bioidentical regimen is typically where most women begin. The Menopause Society 2022 Hormone Therapy Position Statement and the SOGC Guideline No. 422a recommend approved products as a strong evidence-backed option when they are clinically appropriate. At a dedicated BHRT clinic, approved products are one component of a broader toolkit rather than a default protocol.

Compounded BHRT

Compounded BHRT is custom-prepared by a compounding pharmacy based on a specific prescription. The hormones are still bioidentical, but the formulation is tailored: a specific combination of estradiol and estriol in a cream base, a dose strength not commercially available, or a compounded DHEA preparation in a form not available as a Canadian finished product. Compounded preparations are particularly valuable for patients who:

• ✓Need a precise dose or combination not available in commercial products
• ✓Benefit from combined hormones in a single preparation (such as BiEst, estradiol with estriol)
• ✓Need a compounded DHEA preparation in a form, dose, or combination not available as a finished Canadian product
• ✓Cannot tolerate ingredients in commercial products (adhesives, dyes, fillers)
• ✓Want a regimen tuned to individual physiology, response, and clinical goals

Compounded BHRT in Canada is regulated provincially through pharmacy colleges rather than federally through Health Canada drug approval pathways. The individual hormone ingredients are Health Canada-approved drug substances; the compounding pharmacies that prepare the formulations follow national standards set by NAPRA (the National Association of Pharmacy Regulatory Authorities). Quality and consistency depend on the compounding pharmacy. Reputable compounding pharmacies follow strict standards, but compounded products do not undergo the same large-scale clinical trials as approved finished products.

Which one is right for you?

There isn’t a universal answer. For some patients, a Health Canada-approved regimen is the right fit from the start: stable dosing, large-scale evidence, and straightforward pharmacy access. For others, a compounded preparation better matches their physiology, symptoms, or goals: a precise dose, a combined formulation, or an ingredient like DHEA in a form not available commercially. Many patients use both at different points in their care.

The decision belongs to you and your prescriber, and it should be a clinical conversation rather than a default protocol. At a dedicated BHRT clinic, the right starting point is determined by who you are, not by what is on the standard formulary.

The 2025-2026 shift: Why hormone therapy warnings are being rewritten

Anyone researching BHRT today is reading information from two very different eras. Most online content about hormone therapy was written under the shadow of the 2002 Women’s Health Initiative (WHI) and the FDA “black box” warnings that followed in 2003. That framework changed substantially in late 2025.

What happened

On November 10, 2025, the FDA and U.S. Department of Health and Human Services announced they would initiate removal of the “black box” warning on estrogen-containing menopausal hormone therapy products. On February 12, 2026, the FDA approved the first six product label changes, removing the warning statements about cardiovascular disease, breast cancer, and probable dementia from products including Prometrium, Divigel, Bijuva, Cenestin, Enjuvia, and Estring. Twenty-nine drug companies are in the process of updating their hormone therapy labels.

Why it happened

The original black box warning was based primarily on the WHI study, which recruited women whose average age was 63, more than a decade past the typical menopause onset. Subsequent reanalysis of the WHI data by age cohort, along with the KEEPS and ELITE trials, demonstrated that the original headline risk findings did not apply to women initiating hormone therapy under 60 or within 10 years of menopause. The benefits in that population outweigh the risks for most women.

What it means in Canada

The FDA decision applies to U.S.-approved product labels. Health Canada has not yet issued identical labelling changes, but the regulatory direction aligns with the updated international evidence base. The Canadian Menopause Society publicly welcomed the FDA decision on November 12, 2025, and stated it will continue engaging with Health Canada to ensure Canadian labelling reflects current evidence.

For Canadian patients, this matters in three practical ways:

The simpler takeaway: the headline “hormones cause cancer” framing many women grew up with was built on a study population that does not represent most women considering BHRT today. The evidence base has matured, regulators are catching up, and informed individual decision-making is the new standard.

Who can prescribe BHRT in Canada?

Several types of qualified clinicians can prescribe BHRT in Canada. Which one you see depends on what province you live in, what your symptoms are, and what kind of care you want.

Nurse Practitioners (NPs)

Nurse practitioners hold full prescriptive authority in every province and territory in Canada. They can independently assess hormone health, order lab work, prescribe Health Canada-approved BHRT, and prescribe compounded BHRT where clinically indicated. No physician referral is required to see an NP. At Red Leaf Wellness, our NP team manages a significant portion of our BHRT cases.

Physicians (MDs)

Family physicians, gynecologists, and endocrinologists can all prescribe BHRT. The challenge in Canada is access: wait times for menopause-focused appointments through the public system are often long, and not all family physicians have advanced training in BHRT. Patients sometimes seek out menopause-focused private care for this reason.

Naturopathic Doctors (NDs)

Naturopathic doctor prescribing authority for BHRT varies significantly by province and is more limited than many patients realize. In Alberta, naturopathic doctors hold no pharmaceutical prescribing authority and cannot prescribe pharmaceutical-grade estradiol, progesterone, or testosterone. In British Columbia and Ontario, naturopathic doctors who have completed additional certification (CONO certification in Ontario) hold limited prescribing authority for hormone health: bioidentical estrogen and progesterone in topical or suppository form only. Oral, injectable, and patch forms remain outside their scope, as does testosterone (a controlled substance, which NDs cannot prescribe in any province). In Saskatchewan, Manitoba, and the Atlantic provinces, ND prescribing authority is either absent or very limited.

This does not mean naturopathic medicine is less valuable for hormone health. NDs bring a comprehensive toolkit of functional testing, botanical medicine, clinical nutrition, and root-cause investigation that nurse practitioners do not. For patients who are wary of pharmaceuticals, cannot take them for medical reasons (including hormone-sensitive cancer history), or want to address underlying drivers first, the ND pathway is often the right starting point. At Red Leaf Wellness, our naturopathic team works in shared care with our nurse practitioner team, so patients can move between or combine pathways as their care evolves. For a detailed comparison, see Naturopathic Medicine or Nurse Practitioner: Which Best Fits Your Hormone Health Journey?

Do I need a referral?

You do not need a referral to see a Red Leaf Wellness NP or ND for BHRT. Private menopause-focused clinics across Canada generally operate on this model. The Canada Health Act covers publicly insured services delivered through provincial health plans, but does not cover the consultation-based BHRT care that is most common in Canadian menopause clinics. We explain what is and is not covered up front so there are no surprises.

What does BHRT cost in Canada, and is it covered by insurance?

BHRT cost in Canada has two components: the consultation and the medication. The two are billed and covered differently.

Consultation fees

Most menopause-focused BHRT clinics operate outside the publicly insured system. Initial consultations typically range from $200 to $450 depending on the prescriber and the depth of assessment. Follow-up visits are usually shorter and lower-cost. Many extended health benefit plans reimburse a portion of NP, ND, or counselling services. Coverage varies significantly by employer plan.

Medication cost

Health Canada-approved bioidentical products (estradiol patches, micronized progesterone, estradiol gel) are typically covered by most private extended health plans, the same way any prescription medication would be. Provincial drug plans cover some of these products for eligible patients (seniors, low-income residents) under their formulary rules. Out-of-pocket cost for approved products usually ranges from $30 to $90 per month depending on the regimen.

Compounded BHRT is generally not covered by provincial drug plans. Some private extended health benefit plans cover compounded prescriptions, but many do not. Out-of-pocket monthly cost for a compounded regimen typically ranges from $60 to $200 depending on the formulation and the pharmacy.

Lab work

Lab work coverage depends on who orders it. Nurse practitioners can order provincially funded bloodwork (standard hormone panels, thyroid panels, metabolic markers, and follow-up monitoring) through the provincial health system, typically at no direct cost to the patient. Naturopathic doctors cannot order provincially funded labs; lab work requisitioned by an ND is private and fee-for-service, paid directly, through extended health benefits, or via a Health Spending Account.

NDs also access functional testing the provincial system does not offer at all (DUTCH panels, salivary hormone analysis, organic acid testing, comprehensive stool analysis). Advanced hormone and endocrine testing can be ordered through either pathway when clinically indicated, but it is always billed separately.

Potential Benefits of BHRT

The benefits of BHRT, particularly when started in the right window, are well-documented in the menopause literature. Some are familiar to most readers; others (cardiovascular protection, skin and connective tissue, metabolic function) are less commonly discussed but supported by current evidence.

Risks, side effects, and what the current evidence actually says

Honest discussion of BHRT risk requires more nuance than most online sources provide. Here is what the current evidence supports.

Common side effects

Bloating, breast tenderness, headaches, mood changes, and irregular bleeding can occur, particularly in the first few months of treatment. Most of these resolve as the body adjusts or with dose adjustment. Persistent side effects are a reason to reassess the regimen, not necessarily to discontinue therapy.

The cancer risk question, in context

The conversation about hormone therapy and breast cancer risk has changed significantly since the original WHI findings were published in 2002. Subsequent reanalysis by age cohort, the KEEPS and ELITE trials, and the 2022 Menopause Society position statement substantially refined our understanding. The 2025-2026 FDA labelling changes are the regulatory expression of that shift.

For women under 60 or within 10 years of menopause onset, the absolute increase in breast cancer risk associated with combined estrogen-progestogen therapy is small, and the benefits for symptom relief and bone protection often outweigh that risk. The risk profile shifts as women age further out from menopause. Estrogen-only therapy in women without a uterus does not appear to increase breast cancer risk in most studies, and recent long-term WHI follow-up data has suggested it may be associated with lower breast cancer incidence in some cohorts.

This is not a guarantee of safety. It is a recognition that the older “hormones cause cancer” framing was built on an older patient population and combined synthetic regimens that are no longer the standard of care. The conversation with your prescriber should consider your personal history, family history, age, and time since menopause, not a one-size-fits-all warning.

Cardiovascular risk

Hormone therapy started in the right window (under 60 or within 10 years of menopause) is associated with a favourable or neutral cardiovascular profile in current evidence. Starting hormone therapy in older women, more than 10 years past menopause onset, carries higher cardiovascular risk and is generally not recommended unless the symptom burden is severe and other options have failed.

Blood clot risk

Oral estrogen carries a small increase in venous thromboembolism (blood clot) risk. Transdermal estrogen (patches, gels) does not appear to carry this risk and is preferred for women with cardiovascular risk factors, history of clots, or obesity.

The compounded BHRT safety question

Compounded BHRT has not been studied at the same scale as Health Canada-approved products. Dose consistency depends on the compounding pharmacy. The Menopause Society’s 2022 position statement specifically notes safety concerns with compounded bioidentical hormone therapy, including minimal government regulation, dosing inconsistencies, and lack of large-scale efficacy data. This is one of the reasons reputable BHRT prescribers in Canada lead with approved products and use compounded preparations only when there is a clinical reason.

Accessing BHRT in Canada: what to expect

If you are considering BHRT, here is the typical path from first inquiry to first prescription.

Initial consultation

The first appointment is the longest, usually 45 to 75 minutes. Your prescriber will take a detailed history of symptoms, menstrual or menopausal status, personal and family medical history, current medications, and lifestyle factors. They will discuss your goals: symptom relief, bone protection, mood, sleep, or all of the above.

Lab work

Most BHRT prescribers will order baseline lab work: estradiol, FSH, progesterone, testosterone, thyroid function, and sometimes additional panels depending on your history. Lab interpretation in perimenopause is complex because hormone levels fluctuate. Many experienced prescribers weight symptoms heavily alongside numbers.

Treatment plan

Based on your history and lab results, your prescriber will recommend a regimen. For most women, this starts with a Health Canada-approved bioidentical product. Common starting regimens include a transdermal estradiol patch combined with oral micronized progesterone, or estradiol gel with a progesterone alternative based on individual factors.

Follow-up

The first follow-up usually occurs 6 to 12 weeks after starting therapy. This is when your prescriber assesses symptom response, side effects, and whether the dose or formulation needs adjustment. Subsequent follow-ups are typically every 3 to 6 months in the first year, then annually once a regimen is stable.

Alternatives and complements to BHRT

BHRT is not the right choice for everyone, and not every woman wants to start with prescription therapy. The following approaches can be used alongside BHRT or instead of it.

Lifestyle interventions

The evidence for lifestyle factors in menopause symptom management is strong. Regular resistance exercise improves bone density, mood, sleep, and metabolic health. A balanced diet, adequate protein, stress management, and consistent sleep hygiene all reduce symptom burden. These are foundational regardless of whether BHRT is added.

Non-hormonal medications

For women who cannot or choose not to take hormone therapy, non-hormonal options for vasomotor symptoms include certain SSRIs and SNRIs (such as venlafaxine and paroxetine), gabapentin, and fezolinetant (Veozah), which targets the brain pathway responsible for hot flashes and is approved by Health Canada specifically for vasomotor symptoms. These can be effective and are sometimes used alongside hormone therapy.

Acupuncture and integrative therapies

Acupuncture has reasonable evidence for reducing the frequency and intensity of hot flashes and improving sleep in menopausal women. At Red Leaf Wellness, acupuncture is often integrated into hormone health care as a complement to BHRT or as a standalone option for women who prefer non-prescription approaches.

Herbal and natural supports

Black cohosh, evening primrose, and certain phytoestrogen-rich foods are commonly used. Evidence varies by product and indication. Supplements are not regulated to the same standard as prescription medications, and quality varies significantly. Discuss any supplement with your prescriber, particularly if you are also taking BHRT or other medications.

Conclusion: Finding the Right BHRT Path in Canada

BHRT in Canada is more accessible, better understood, and better regulated than it was a decade ago. The 2025-2026 FDA labelling changes, the alignment of the Canadian Menopause Society, and the body of evidence behind the 2022 Menopause Society and SOGC guidelines together represent the biggest shift in hormone therapy guidance since the WHI study itself. For most women starting hormone therapy under 60 or within 10 years of menopause, the benefit-to-risk profile is more favourable than older messaging suggested.

Approved bioidentical products are the new starting point for most women. Compounded BHRT remains an important tool for the specific clinical situations that warrant it. The most important step is choosing a prescriber who understands the full landscape: who can explain why a particular formulation is being recommended, who places your individual history and goals at the centre of the plan, and who follows current evidence rather than marketing claims.

Learn More From Our Blog: